GlassScriptPhysician profile
William Reed Shimberg
NPI 1790147940
$2,882.27
in general payments reported to CMS, 2019-2025
27 companies · $1,822 in 2025
The $1,822 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2024: $936 · 2025: $1,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,758.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $537.79 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $294.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $293.44 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $273.84 | 2024-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.19 | 2019-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $181.23 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $163.27 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $126.55 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.78 | 2024-2025 | Xifaxan |
| Abbvie INC. | $94.17 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.84 | 2024-2025 | |
| Inspire Medical Systems, INC. | $79.75 | 2024-2025 | Inspire |
| Lilly USA, LLC | $55.11 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $48.44 | 2024-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Boston Scientific Corporation | $39.56 | 2024-2025 | Watchman Flx, Watchman Access System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $32.66 | 2024 | |
| Glaxosmithkline, LLC. | $30.96 | 2025 | Shingrix |
| Neuronetics, INC. | $29.14 | 2025 | Neurostar Tms Therapy System |
| Abbott Laboratories | $24.34 | 2025 | Freestyle Libre 2 |
| Corcept Therapeutics | $23.26 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $22.82 | 2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $22.58 | 2024 | Edarbi |
| Otsuka America Pharmaceutical, INC. | $22.05 | 2024 | Rexulti |
| Astellas Pharma US INC | $20.37 | 2024 | Veozah |
| Lucid Diagnostics INC. | $19.15 | 2025 | |
| Philips North America LLC | $18.52 | 2024 | (Ck7) Extended Holter |
| Kowa Pharmaceuticals America, INC. | $17.47 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shimberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.